This site is intended for healthcare professionals

The phase III REAL 4 of Sogroya shows efficacy in growth hormone deficiency.

Read time: 1 mins
Published:14th Jun 2022

Novo Nordisk announced results of once-weekly Sogroya (somapacitan) injection in helping children achieve growth targets of annualised height velocity (AHV).

The phase III REAL 4 (REversible ALbumin) study (NCT03811535) is part of the ongoing REAL clinical study programme and was designed to evaluate the efficacy and safety of somapacitan injection in children with growth disorders, comprising a 52-week main phase followed by a three-year extension period. Two-hundred growth hormone (GH) treatment naïve, prepubertal children with GHD (74.5% male) were randomly assigned in a 2:1 ratio to receive weekly subcutaneous 0.16 mg/kg/week Sogroya (n=132) or daily subcutaneous 0.034 mg/kg/day somatropin (Norditropin) (n=68).

In the phase III study, REAL 4, Sogroya showed a not significantly different AHV of 11.2 cm/year, compared to 11.7 cm/year for Norditropin. Based on the main phase results of REAL 4, once-weekly Sogroya was shown to work as well as daily Norditropin for children with GHD, meeting its primary endpoint of non-inferiority. The most common AEs observed in at least 5% were events commonly observed in children, including headache, nasopharyngitis, pyrexia, pain in extremity, bronchitis and vomiting. These results from the REAL 4 study, in prepubertal children with growth hormone deficiency (GHD), were presented at the Endocrine Society’s Annual Meeting (ENDO 2022) in Atlanta, Georgia (US).

Condition: Growth Hormone Deficiency
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.